VITRNasdaq StockholmHealth CareIFRS · SEK

Vitrolife

Vitrolife Group is a global provider of medical devices and genetic testing solutions focused on reproductive health. Since its inception in 1994, the company has expanded through innovative research, product development, and strategic acquisitions. Vitrolife offers a comprehensive range of products and services that support the entire reproductive-health journey, aiming to improve treatment outcomes and patient access worldwide. The company is committed to sustainability and continuous improvement in its operations and offerings.

Ask about the company
Revenue3,440m SEK
−4.7 %y/y
Operating profit (EBIT)-4,835m SEK
−717.5 %y/y
EBIT margin-140.6%
−162.2 ppy/y
Net income47.0m SEK
−90.9 %y/y

Fiscal year 2025 · change from previous year

Development 2020–2025

-6,000-4,000-2,00002,0004,000m SEK2020: 1,246 m SEK2020: EBIT 370 m SEK20202021: 1,681 m SEK2021: EBIT 435 m SEK20212022: 3,234 m SEK2022: EBIT 654 m SEK20222023: 3,512 m SEK2023: EBIT -3,589 m SEK20232024: 3,609 m SEK2024: EBIT 783 m SEK20242025: 3,440 m SEK2025: EBIT -4,835 m SEK20253,440-4,835
RevenueOperating profit (EBIT)
Ask Clarifo about Vitrolife

Business

Share of revenue
Consumables45 %

Includes media and disposable devices for IVF treatments.

Technologies30 %

Comprises time-lapse systems and lasers for reproductive health.

Genetics25 %

Offers genetic testing and analysis services for reproductive health.

Customers

Vitrolife serves a diverse range of customers in the reproductive health sector, including fertility clinics, hospitals, and healthcare professionals specializing in IVF and genetic testing. These customers rely on Vitrolife's comprehensive suite of products and services to enhance treatment outcomes and ensure high-quality patient care. The company's innovative solutions, such as EmbryoScope® and genetic testing services, are designed to meet the specific needs of reproductive health professionals. Vitrolife's commitment to sustainability and quality further strengthens its appeal to customers seeking reliable and effective reproductive health solutions.

Fertility Clinics

Purchase IVF products and technologies to improve treatment outcomes.

Hospitals

Use genetic testing solutions for comprehensive reproductive care.

Healthcare Professionals

Rely on advanced monitoring systems like EmbryoScope®.

Strategy

Vitrolife's strategic priorities focus on owning the platform, innovating to expand leadership, accelerating growth in key markets, optimizing the go-to-market model, and driving operational excellence. The company aims to sustain profitable growth while ensuring sustainability in its operations. Recent acquisitions, such as eFertility, complement in-house development and enhance the product portfolio. Increased R&D investments are driving the launch of new products and services, positioning Vitrolife as a leader in reproductive health solutions.

Own the platformMedium term

To integrate products and services for better customer solutions.

Accelerate growth in key marketsShort term

To increase market share and revenue.

Geography

Vitrolife operates in approximately 125 markets worldwide, with significant presence in the Americas, EMEA, and APAC regions. The company has strategically increased investments in key markets such as the US and China, leading to market share gains. Manufacturing and operational facilities are located in several countries, including Sweden, Spain, Brazil, the US, Denmark, and Japan. This global footprint allows Vitrolife to effectively serve a diverse customer base and adapt to regional market demands.

Risks

Vitrolife faces several strategic and operational risks, including macroeconomic fluctuations, regulatory changes, and competitive pressures in the reproductive health industry. The company must navigate financial risks related to currency fluctuations and interest rates, given its global operations. Additionally, maintaining compliance with international sanctions and managing supply chain disruptions are critical to sustaining operations. The company's commitment to sustainability also requires careful management of environmental risks.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Regulatory changes1Competitive pressures3
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Regulatory changesImpact: HighLikelihood: Medium

    Affect product approvals and market access.

  2. Macroeconomic fluctuationsImpact: High

    Impact global demand and pricing strategies.

  3. Competitive pressuresImpact: MediumLikelihood: Low

    Challenge market position and pricing.

Ask Clarifo about Vitrolife

Accounting

Judgemental items
Revenue recognition timing

Affects quarterly financial comparisons and earnings stability.

Fair value measurements

Impact valuations of financial assets and liabilities.

Similar listed companies

Publicly listed companies with a comparable business focus.

Getinge

GETI-B · Health Care

AddLife

ALIF-B · Health Care

Revvity, Inc

RVTY · Laboratory Analytical Instruments

MetLife, Inc

MET · Life Insurance

BioLife Solutions, Inc

BLFS · Electromedical & Electrotherapeutic Apparatus

Nightingale Health Oyj

HEALTH · Health Information Services

Last updated: 24/09/2026